PrandiMet(R), First Repaglinide And Metformin HCl Fixed Dose Combination Therapy, Now Available In The United States

PrandiMet(R), First Repaglinide And Metformin HCl Fixed Dose Combination Therapy, Now Available In The United States
Novo Nordisk and Sciele Pharma, Inc., a Shionogi Company, announced the availability of PrandiMet® (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the short-acting secretagogue repaglinide (also known as Prandin®) and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.

New Open-Source Software Permits Faster Desktop Computer Simulations Of Molecular Motion

Whether vibrating in place or taking part in protein folding to ensure cells function properly, molecules are never still. Simulating molecular motions provides researchers with information critical to designing vaccines and helps them decipher the bases of certain diseases, such as Alzheimer's and Parkinson's, that result from molecular motion gone awry. In the past, researchers needed either supercomputers or large computer clusters to run simulations. Continue reading ...

BioIQ Supports American Heart Month To Raise Awareness About Heart Disease, The #1 Killer Of Women

BioIQ Supports American Heart Month To Raise Awareness About Heart Disease, The #1 Killer Of Women
Yes, the truth sometimes hurts. But when it comes to women's health, it's better to face the facts: one in four women in the United States dies of heart disease. Although significant progress has been made in increasing awareness among women, most people fail to make the connection between risk factors and their personal risk for developing heart disease.